Ro-3306 te N-desmethyl Netupitant The consecutive administration of Ginsenoside

The consecutive administration of Ginsenoside Rb2 also reduces virus titers in the bowels of RV-infected mice[2]

Smiles: C[C@@H]1O[C@@H](O[C@H]2[C@H](OC(=O)/C=C/C3=CC(O)=C(O)C=C3)[C@@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](OCCC3C=CC(O)=C(O)C=3)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O

(2015) Nat Commun

SNIPER(ER)87

CAS Number: 191089-60-8

Ro-3306 te N-desmethyl Netupitant The consecutive administration of GinsenosideRO 3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO 3306 induced G2 M phase cell cycle arrest and apoptosis in a dose and time dependent manner. RO 3306 downregulated expression of the antiapoptotic proteins Bcl 2 and survivin and blocked p53 mediated induction of p21 and MDM2. RO 3306 actively enhances downstream p53 signaling to promote apoptosis. Product information CAS Number: 872573 93 8